V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220022264 | 220008475 | null | 84.7 | null | 2014-07-06 | 2014-07-06 | PONATINIB | 02 | N | 220032108 | CISPLATIN + GEMCITABINE |
| 220022265 | 220008497 | 1.72 | 103 | Curative (C) | 2015-10-12 | 2015-10-12 | Carboplatin + Etoposide iv&po | N | N | 220032156 | CARBOPLATIN + ETOPOSIDE |
| 220022266 | 220008625 | 1.74 | 76 | Curative (C) | 2016-10-08 | 2016-11-06 | Fludarabine + Melphalan RIC Allo | N | N | 220032532 | METHOTREXATE |
| 220022267 | 220019904 | 0 | 78 | Curative (C) | 2017-06-21 | 2017-08-19 | Irinotecan + Modified De Gramont | N | N | 220033250 | DOCETAXEL |
| 220022268 | 220008961 | 1.53 | null | Palliative (P) | 2017-08-23 | 2018-02-10 | PACLITAXEL | N | N | 220033807 | PACLITAXEL |
| 220022269 | 220009162 | 1.68 | 55.8 | Curative (C) | 2015-09-15 | 2015-09-27 | LENALIDOMIDE | N | N | 220034495 | SORAFENIB |
| 220022272 | 220022119 | null | 53 | Palliative (P) | 2016-10-19 | 2016-10-19 | BEP 5 Day | N | N | 220036062 | BUSULFAN + CYCLOPHOSPHAMIDE |
| 220022273 | 220009513 | 1.77 | 68 | Curative (C) | 2016-12-05 | 2016-12-15 | Thalidomide 50mg | N | N | 220036121 | FIGARO TRIAL |
| 220022274 | 220009581 | 1.69 | 66.7 | Disease modification (D) | 2019-04-29 | 2019-05-30 | Cyclophosphamide High Dose | N | Y | 220036432 | DABRAFENIB + TRAMETINIB |
| 220022275 | 220009646 | null | null | Disease modification (D) | 2015-05-13 | 2016-01-31 | Bortezomib | Y | N | 220036641 | BUSULPHAN + FLUDARABINE |
| 220022276 | 220009693 | 1.72 | 68 | null | null | 2018-12-20 | ALL UKALL60+ TRIAL | N | N | 220004682 | MIDAC |
| 220022277 | 220009718 | 1.71 | 71.8 | Curative (C) | null | 2019-07-19 | Cetuximab 7 day (>Cycle 2) | 2 | N | 220018242 | CAPECITABINE |
| 220022280 | 220004371 | 1.6 | 0 | Curative (C) | 2014-07-18 | 2014-08-13 | IMATINIB | 2 | N | 220007789 | IMATINIB |
| 220022281 | 220004505 | 1.55 | 67.7 | Disease modification (D) | 2014-09-30 | 2014-10-05 | Azacitidine | 2 | null | 220010889 | AZACITIDINE |
| 220022282 | 220012389 | 1.52 | 75 | Adjuvant (A) | 2017-05-09 | 2017-05-09 | DA 3+8 | 2 | N | 220011747 | DA |
| 220022283 | 220005087 | 1.66 | null | Curative (C) | 2018-03-10 | 2018-03-10 | DA | N | N | 220020158 | DA |
| 220022284 | 220005094 | null | null | Curative (C) | 2018-10-17 | 2018-10-21 | Nilotinib | N | N | 220020160 | NILOTINIB |
| 220022285 | 220005221 | 1.67 | null | Curative (C) | 2018-01-04 | 2018-01-04 | Nilotinib | 2 | N | 220020435 | NILOTINIB |
| 220022287 | 220005316 | null | 92.6 | Curative (C) | 2014-12-09 | 2015-02-09 | AML Int Guide HD Cytarabine (3 + 4) | N | N | 220020591 | CYTARABINE HIGH DOSE |
| 220022288 | 220019361 | 1.61 | 51.2 | Curative (C) | 2014-06-26 | 2014-07-03 | FLAG + Idarubicin | N | N | 220020646 | FLAG + IDARUBICIN |
| 220022289 | 220005354 | 0 | 42.6 | Curative (C) | 2020-01-11 | 2020-03-09 | FLAG + Idarubicin | N | null | 220020673 | FLAG + IDARUBICIN |
| 220022290 | 220005673 | 1.69 | 119.6 | Adjuvant (A) | 2019-01-29 | 2019-01-31 | FLAG + Idarubicin | N | N | 220021572 | FLAG + IDARUBICIN |
| 220022291 | 220005762 | 1.64 | 53.5 | Curative (C) | 2017-11-11 | 2017-11-11 | AML 19 TRIAL | Y | N | 220021789 | AML19 TRIAL |
| 220022292 | 220006274 | 0 | null | Curative (C) | 2014-07-04 | 2014-07-04 | Cytarabine Low Dose | N | N | 220023793 | CYTARABINE |
| 220022293 | 220006283 | null | 12.2 | Curative (C) | 2018-11-04 | 2019-02-02 | AML MyeChild 01 IT Cyt | null | N | 220023821 | NOT MATCHED |
| 220022294 | 220007216 | null | null | null | 2015-04-01 | 2015-07-28 | Alemtuz+Fludara+Melphalan RIC MUD | N | null | 220027691 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220022295 | 220007321 | null | 77.8 | Disease modification (D) | 2017-01-11 | 2017-04-15 | AML 18 TRIAL | 1 | N | 220028203 | AML18 TRIAL |
| 220022296 | 220007949 | 1.61 | 52.4 | Curative (C) | 2019-03-09 | 2019-03-17 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | N | 220030435 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220022297 | 220007966 | null | 82.2 | Curative (C) | 2019-03-21 | 2019-03-22 | AML 18 TRIAL | 1 | N | 220030475 | AML18 TRIAL |
| 220022298 | 220017842 | 1.73 | 61.35 | Disease modification (D) | 2018-06-08 | 2018-07-14 | Methotrexate intrathecal | N | N | 220030478 | METHOTREXATE INTRATHECAL |
| 220022299 | 220007984 | 1.74 | 90 | null | 2015-05-14 | 2015-05-23 | FLAG | N | N | 220030497 | FLAG |
| 220022300 | 220014446 | 1.85 | null | Curative (C) | 2019-05-01 | 2019-12-30 | CYCLOPHOSPHAMIDE + FLUDARABINE | 02 | null | 220030955 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220022301 | 220008241 | 1.67 | 63 | Curative (C) | 2014-05-09 | 2015-08-10 | BOSUTINIB | N | N | 220031302 | BOSUTINIB |
| 220022302 | 220008267 | 1.75 | 76.1 | Curative (C) | 2018-09-11 | 2018-10-26 | Triple / Double Intrathecal Therapy | 2 | N | 220031415 | TRIPLE INTRATHECAL |
| 220022303 | 220008476 | 1.67 | 86.5 | Curative (C) | 2014-11-03 | 2014-11-18 | Arsenic trioxide + Tretinoin | N | null | 220032108 | ARSENIC TRIOXIDE + TRETINOIN |
| 220022304 | 220021575 | 1.6 | null | Disease modification (D) | 2017-08-03 | 2017-08-19 | Cytarabine intrathecal | N | N | 220033250 | CYTARABINE INTRATHECAL |
| 220022305 | 220008961 | null | 66.8 | null | 2018-06-09 | 2018-06-09 | Fludarabine + Melphalan RIC Allo | 02 | N | 220033807 | FLUDARABINE + MELPHALAN |
| 220022306 | 220009163 | 1.6 | 80 | Curative (C) | 2015-11-14 | 2015-11-16 | Cytarabine intrathecal | N | N | 220034495 | CYTARABINE INTRATHECAL |
| 220022309 | 220022276 | 1.74 | 62.8 | Palliative (P) | 2016-11-10 | 2016-11-23 | Trastuzumab 21 day loading dose | N | N | 220036062 | MITOXANTRONE + TRETINOIN |
| 220022310 | 220009582 | 1.8 | 76 | Disease modification (D) | 2019-04-17 | 2019-05-30 | Carboplatin AUC 6 - 10 | N | N | 220036432 | CYCLOPHOSPHAMIDE + FLUDARABINE + THIOTEPA |
| 220022312 | 220016749 | null | 105 | Curative (C) | 2017-03-09 | 2017-05-24 | Cytarabine High Dose | N | null | 220011747 | CYTARABINE HIGH DOSE |
| 220022313 | 220005087 | 1.6 | 90 | Curative (C) | 2018-03-09 | 2018-03-10 | Nilotinib | N | N | 220020158 | NILOTINIB |
| 220022314 | 220005221 | null | 102.4 | Curative (C) | 2018-05-02 | 2018-08-28 | Nilotinib | N | N | 220020435 | NILOTINIB |
| 220022316 | 220005316 | 1.79 | 78.4 | Curative (C) | 2015-03-09 | 2015-03-09 | FLAG + Idarubicin | N | null | 220020591 | FLAG + IDARUBICIN |
| 220022317 | 220019361 | 1.83 | 90.4 | Curative (C) | 2014-07-04 | 2014-07-04 | Trial Unspecified | Y | N | 220020646 | TRIAL |
| 220022318 | 220005354 | null | 62 | Disease modification (D) | 2020-02-23 | 2020-03-09 | ALL Int Guide B Ind Ph 1 PegAsp | 2 | N | 220020673 | NOT MATCHED |
| 220022319 | 220005673 | null | 51.5 | Curative (C) | 2019-01-30 | 2019-03-18 | AML18 PILOT TRIAL | N | N | 220021572 | PILOT TRIAL |
| 220022320 | 220017158 | 1.86 | 84 | Curative (C) | 2018-04-02 | 2018-04-03 | Rituximab | N | N | 220021789 | RITUXIMAB |
| 220022321 | 220007321 | null | 98.9 | Curative (C) | 2017-05-22 | 2017-05-24 | AML 18 TRIAL | 1 | N | 220028203 | AML18 TRIAL |
| 220022322 | 220014360 | 1.62 | 94.6 | Disease modification (D) | 2005-10-05 | 2019-07-11 | Triple / Double Intrathecal Therapy | 01 | N | 220030435 | TRIPLE INTRATHECAL |